DelveInsight has launched a new report on “Acute Respiratory Distress Syndrome (ARDS) – Pipeline Insight 2020”.
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs making breathing difficult or impossible.
The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others. Whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions.
The few symptoms of ARDS are, shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risk-factors that may escalate the risk for ARDS. This involves obesity, alcohol abuse, chemotherapy, low-protein in blood.
The launch of the emerging therapies is expected to significantly impact Postherpetic Neuralgia treatment scenario in the upcoming years:-
Drugs covered:
- Traumakine
- Bio-11006
- Ulinastatin
- MultiStem
- Solnatide (AP301)
- APN01 (GSK2586881)
- GSK2862277
- IC14
- Remodulin (Treprostinil Inhalation Solution)
The key players in Postherpetic Neuralgia market are:
- Faron Pharmaceuticals
- BioMarck Pharmaceuticals
- Techpool Bio-Pharma
- Athersys
- APEPTICO Forschung und Entwicklung GmbH
- Apeiron Biologics/GlaxoSmithKline
- GlaxoSmithKline
- Implicit Bioscience
- United Therapeutics
Acute Respiratory Distress Syndrome (ARDS) Analytical Perspective by DelveInsight
- In-depth Acute Respiratory Distress Syndrome (ARDS) Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
- Acute Respiratory Distress Syndrome (ARDS) Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
Scope of the report
- The Acute Respiratory Distress Syndrome (ARDS) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acute Respiratory Distress Syndrome (ARDS) across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Acute Respiratory Distress Syndrome (ARDS) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Acute Respiratory Distress Syndrome (ARDS) research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acute Respiratory Distress Syndrome (ARDS).
Report highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Acute Respiratory Distress Syndrome (ARDS).
- In the coming years, the Acute Respiratory Distress Syndrome (ARDS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Acute Respiratory Distress Syndrome (ARDS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Acute Respiratory Distress Syndrome (ARDS) treatment market. Several potential therapies for Acute Respiratory Distress Syndrome (ARDS) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Acute Respiratory Distress Syndrome (ARDS) market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
- What are the current options for Acute Respiratory Distress Syndrome (ARDS) treatment?
- How many companies are developing therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- How many Acute Respiratory Distress Syndrome (ARDS) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Acute Respiratory Distress Syndrome (ARDS) market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Acute Respiratory Distress Syndrome (ARDS) therapies?
- What are the clinical studies going on for Acute Respiratory Distress Syndrome (ARDS) and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Acute Respiratory Distress Syndrome (ARDS)?
- How many patents are granted and pending for the emerging therapies for the treatment of Acute Respiratory Distress Syndrome (ARDS)?
Table of Contents:
1. Report Introduction
2. Acute Respiratory Distress Syndrome (ARDS)
2.1. Overview
2.2. History
2.3. Acute Respiratory Distress Syndrome (ARDS) Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Acute Respiratory Distress Syndrome (ARDS) Diagnosis
2.6.1. Diagnostic Guidelines
3. Acute Respiratory Distress Syndrome (ARDS) Current Treatment Patterns
3.1. Acute Respiratory Distress Syndrome (ARDS) Treatment Guidelines
4. Acute Respiratory Distress Syndrome (ARDS) - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acute Respiratory Distress Syndrome (ARDS) companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Acute Respiratory Distress Syndrome (ARDS) Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Acute Respiratory Distress Syndrome (ARDS) Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Acute Respiratory Distress Syndrome (ARDS) Late Stage Products (Phase-III)
7. Acute Respiratory Distress Syndrome (ARDS) Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Respiratory Distress Syndrome (ARDS) Discontinued Products
13. Acute Respiratory Distress Syndrome (ARDS) Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
Detailed information in the report?
14. Acute Respiratory Distress Syndrome (ARDS) Key Companies
15. Acute Respiratory Distress Syndrome (ARDS) Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Acute Respiratory Distress Syndrome (ARDS) Unmet Needs
18. Acute Respiratory Distress Syndrome (ARDS) Future Perspectives
19. Acute Respiratory Distress Syndrome (ARDS) Analyst Review
20. Appendix
21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
